Every epic journey has that moment when the end is in sight. The start of the last lap of the race, the final dramatic encounter with the main villain. On this episode of Oncology for the Inquisitive Mind, that villain is metastatic lung cancer, with a particular focus on EGFR mutant disease. There have been a lot of questions raised about the best next step after the failure of the star of ASCO 2023: osimertinib. Here, Josh and Michael examine three breaking studies that seek to shed some light on the slowly-unravelling mystery of how to best sequence and treat EGFR mutant advanced non-small cell lung cancer.

Finally, as we surpass fifty episodes, we wanted to say a huge thank you to everyone who has joined us on Oncology for the Inquisitive Mind so far. We have gone from two guys completely ignorant to the ways of podcasting to two guys almost completely ignorant to the ways of podcasting with a burgeoning, supportive and engaging community. For that, we cannot thank you enough. We love bringing this content to you, and we cannot wait for the next fifty episodes. We have a lot of exciting stuff yet to come!

Studies

KEYNOTE-789: https://meetings.asco.org/abstracts-presentations/218083

EVEREST: https://meetings.asco.org/abstracts-presentations/218106

WU-KONG6: https://meetings.asco.org/abstracts-presentations/218846

Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.